biphasic insulin aspart 50 — Competitive Intelligence Brief

biphasic insulin aspart 50 (biphasic insulin aspart 50) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin (premixed biphasic formulation). Area: Diabetes.

marketed Insulin (premixed biphasic formulation) Insulin receptor Diabetes Small molecule

Target snapshot

biphasic insulin aspart 50 (biphasic insulin aspart 50) — Novo Nordisk A/S. Biphasic insulin aspart 50 is a premixed insulin formulation that provides rapid-acting insulin aspart combined with intermediate-acting insulin to control blood glucose in diabetes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
biphasic insulin aspart 50 TARGET	biphasic insulin aspart 50	Novo Nordisk A/S	marketed	Insulin (premixed biphasic formulation)	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin (premixed biphasic formulation) class)

1. Novo Nordisk A/S · 2 drugs in this class